is 401

Diisopropylamine dichloroacetate stimulates smooth muscle & strongly inhibits acetylcholinesterase activity.

DN401 is a potent TRAP1 and Hsp90 Inhibitor( IC50 = 79 nM for TRAP1, IC50 = 698 nM for Hsp90) with potent anticancer activity.

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

CORM-401 is an oxidant-sensitive CO-releasing molecule used in the research of oxidative stress-mediated pathologies and inflammation [inflammatory].

BSI-401 is an oral inhibitor of PARP-1. It can inhibit pancreatic cancer either when used alone or in synergy with Oxaliplatin.

CRBN ligand-401 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit cereblon protein. It can be coupled with a target protein ligand via a linker to form a PROTAC.

CC-401 is a specific inhibitor of JNK (Ki: 25-50nM).

JX 401 is a p38α inhibitor.

MM-401 is a specific inhibitor of histone H3K4 methyltransferase MLL1 activity that acts by reprogramming mouse epiblast stem cells to naive pluripotency.

CH 401-Na is a bio-active chemical.

Compound 401 (2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one) is a synthetic DNA-PK inhibitor (IC50 = 0.28 μM) that also targets mTOR but not PI3K.

LEI-401 is a selective and potent NAPE-PLD inhibitor that crosses the blood-brain barrier (IC50: 27 nM).LEI-401 reduces the level of n-acylethanolamines (NAEs) in the brain of free-ranging mice and modulates their emotional behaviour.

CC-401 Hydrochloride (CC401 HCl) is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor (Ki of 25 to 50 nM.)with potential antineoplastic activity.

FK-401 is an inhibitor of chymotrypsin.

TCS-401 is an insulin receptor sensitizing agent; Selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B).

TCS 401 is a selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B) with a Ki value of 0.29 μM.

GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. It exhibits potent cytotoxicity in vitro and in vivo against various B-cell malignancies. GBR-401 induces cell death through antibody-dependent cellular cytotoxicity (ADCC) and direct cytotoxic effects. In severe combined immunodeficiency (SCID) mouse models with various xenografts, GBR-401 effectively eliminates malignant B cells and prolongs survival.

Peptide 401 is an antimicrobial peptide (AMP) derived from the venom of bees and wasps. Peptide 401 induces mast cell degranulation, activating histamine release from peritoneal mast cells. Additionally, peptide 401 exhibits some anti-inflammatory activit

Poloxamer 401 L121 is a block copolymer composed of polyoxyethylene and polyoxypropylene. It is utilized in nanoparticle engineering as a lymphocyte nutrition particle, an inhibitor of multidrug resistance and adjuvant activity, or in the cosmetics industry as a surfactant and emulsifier.

P110δ-IN-1 (PWT-143) is an effective and selective inhibitor of P110δ (IC50: 8.4 nM).

PQ401 (IGF-1R Inhibitor II) suppresses autophosphorylation of IGF-1R domain(IC50<1 μM).

LIBX-A401 is an inhibitor of long-chain acyl-CoA synthetase 4 (ACSL4) with an IC50 value of 0.38 μM. It selectively inhibits ACSL4 over ACSL3 (IC50 exceeding 50 μM) and PPARγ (IC50 exceeding 10 μM).

HSB401 is an orally active FLT3 inhibitor with IC50 values of 28, 5, 72, and 51 nM for FLT3-WT, FLT3-D835Y, FLT3-ITD-F691L, and FLT3-ITD, respectively. It downregulates the FLT3 signaling pathway, inducing cell cycle arrest and apoptosis. HSB401 does not inhibit c-KIT, which reduces the risk of bone marrow suppression. In the MV4-11 xenograft mouse model, HSB401 significantly suppresses tumor growth and is applicable for research in acute myeloid leukemia (AML).

High affinity JNK inhibitor (Ki values are 25-50 nM). Inhibits JNK via competitive binding of the ATP-binding site of active, phosphorylated JNK. Exhibits > 40-fold selectivity for JNK over p38, ERK, IKK2, protein kinase C, Lck and ZAP70. Hepatoprotective. Also inhibits HCMV replication. Uehara et al (2004) c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation. 78 324 PMID:15316358 |Uehara et al (2005) JNK mediates hepatic ischemia reperfusion injury. J.Hepatol. 42 850 PMID:15885356 |Ma et al (2007) A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J.Am.Soc.Nephrol. 18 472 PMID:17202416 |Ma et al (2009) Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat. Lab.Invest. 89 470 PMID:19188913 |Zhang et al (2015) The c-Jun N-terminal kinase inhibitor SP600125 inhibits human cytomegalovirus replication. J.Med.Virol. 87 2135 PMID:26058558 |Vasilevskaya et al (2015) Inhibition of JNK sensitizes hypoxic colon cancer cells to DNA-damaging agents. Clin.Cancer.Res. 21 4143 PMID:26023085